AXL and non-small cell lung carcinoma: Our results revealed that AXL/GAS6 co-expression and N stage (HR 1.81, 95% CI 1.13–2.90, P = 0.013) were independent poor predictors for OS in patients with NSCLC metastases (Tables 3, 4).